Every 8-K that Rocket Pharmaceuticals, Inc. (RCKT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RCKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCKT filings page.
Rocket Pharmaceuticals entered a senior secured term-loan facility with Hercules Capital and other lenders for up to $150.0 million; $35.0 million was funded on September 30, 2026. Further advances include borrower-option tranches, $30.0 million after a clinical milestone, and a final tranche of up to $50.0 million subject to lender investment committee approval.
Interest is the greater of prime or 6.75%, plus 2.40% annually; payments are interest-only through April 1, 2029, with milestone-based extensions. Maturity is October 1, 2030, extendable to October 1, 2031 if the milestone is achieved and no default continues. Substantially all borrower assets secure the loans; a qualified-cash covenant requires 35%–75% of outstanding loans and is not tested when market capitalization exceeds $600.0 million.
Rocket also issued warrants to purchase up to 1,755,853 shares at $2.99 each; 409,699 shares were exercisable after the initial advance, with full exercisability tied to a maximum facility draw. The RP-A501 update reported three Cohort 4 patients treated at the recalibrated dose, with one resolved Grade 3 GGT increase. Cohort 3 was discontinued after serious adverse events in two patients on a C3-inhibitor regimen; pivotal topline results are provisionally targeted for mid-2028.
Rocket Pharmaceuticals, Inc. (RCKT) reported that the U.S. Food and Drug Administration agreed on key elements for the global pivotal Phase 2 trial of gene therapy RP-A501 in Danon disease, including a 12-patient pivotal efficacy population and use of a recalibrated dose.
The FDA reviewed clinical data from the first three male patients treated under a modified protocol at 3.8 × 10¹³ GC/kg, noting no clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome, and confirmed continued enrollment and dosing at this dose. These first three patients count toward the 12-patient pivotal population, leaving nine to enroll, and Rocket expects to complete dosing of the remaining patients by mid-2027. The primary efficacy assessment will occur at 12 months using co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index, which are intended to support a potential accelerated approval pathway.
Rocket Pharmaceuticals, Inc. (RCKT) adopted a new Severance and Change in Control Program covering U.S. employees not already under separate severance arrangements. Eligibility for non-change-in-control severance requires at least one year of service, and benefits are conditioned on signing a release of claims. The program replaces prior severance arrangements but allows individually approved exceptions.
Rocket also entered into updated executive employment arrangements. CEO Gaurav Shah’s agreement provides a base salary of $674,856, a target bonus of 60% of base salary, and cash and COBRA severance enhancements if terminated without Cause or for Good Reason, with larger amounts upon a qualifying Change in Control termination. General Counsel and Chief Corporate Officer Martin Wilson’s agreement provides a base salary of $547,313, a 45% target bonus, and similar severance and COBRA protections, including enhanced change-in-control terms. An amendment for COO Christopher Stevens aligns his severance and change-in-control protections with this framework while leaving the rest of his prior agreement in effect.
Rocket Pharmaceuticals, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026, driven by U.S. FDA approval of KRESLADI™ and monetization of the associated Priority Review Voucher. Second-quarter net income was $123.2 million, compared with a net loss of $68.9 million a year earlier, helped by a $178.2 million gain from the sale of the voucher. Operating expenses declined to $46.9 million from $71.1 million, reflecting lower research and development and general and administrative costs following a prior restructuring.
For the first six months of 2026, Rocket reported net income of $75.6 million versus a net loss of $130.3 million in the prior-year period. Cash, cash equivalents and investments increased to $283.7 million as of June 30, 2026, from $188.9 million at year-end 2025, and the company expects its cash runway to extend into the second quarter of 2028. Rocket highlighted completion of safety observation for the first three Danon disease patients in its modified pivotal Phase 2 trial, continued FDA interactions on the path to rapidly completing this trial, and multiple planned second-half 2026 milestones across its cardiovascular gene therapy programs, including PKP2-ACM and BAG3-DCM, alongside commercial preparations for KRESLADI.
Rocket Pharmaceuticals reported a positive clinical safety update from the initial three patients treated with RP-A501 under the modified protocol in its global, pivotal Phase 2 trial for Danon disease. The patients received a recalibrated dose of 3.8 × 10¹³ GC/kg plus an immunomodulatory regimen of rituximab, sirolimus, and corticosteroids, given sequentially with at least four weeks between infusions. To date, no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns have been observed in these patients.
The pivotal Phase 2 study is designed as a 12-patient, single-arm trial. Rocket is actively engaging with the FDA to align on the path to dosing additional patients and completing the trial and expects an update on the regulatory pathway, as well as a comprehensive Danon disease program update, in the second half of 2026. RP-A501 is a single intravenous AAV9.LAMP2B gene therapy that has demonstrated safety and efficacy in clinical studies and holds multiple U.S. and EU regulatory designations, including RMAT, Fast Track, Rare Pediatric Disease, Orphan Drug, ATMP, and PRIME.
Rocket Pharmaceuticals, Inc. announced leadership changes in its finance organization. John Militello, VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, has resigned effective July 7, 2026 to pursue other opportunities. Joseph Manhede, currently Associate Vice President, Corporate Controller, will become Principal Accounting Officer effective July 8, 2026.
Manhede, age 48, joined Rocket in April 2026 and previously held senior finance roles at Outlook Therapeutics, Amneal Pharmaceuticals, Unilife Corporation and Celator Pharmaceuticals after starting his career at Deloitte. He is a CPA with an MBA from Holy Family University. The company states there are no new compensatory arrangements or related-party transactions tied to his designation.
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross, non-dilutive proceeds. The voucher was granted following FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
Rocket previously reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. Pro forma for the voucher sale, this increases to about $322.6 million, which the company expects will fund operations into the second quarter of 2028.
Rocket Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where holders of 80,774,659 common shares, representing approximately 74.02% of eligible shares, were present in person or by proxy. Stockholders elected seven directors, with support generally above 59 million votes for each nominee.
They ratified EisnerAmper LLP as independent registered accounting firm for the fiscal year ending December 31, 2026, with 79,195,009 votes for and 1,002,656 against. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers and approved a stock option exchange program as described in the 2026 Proxy Statement.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing. The voucher was granted after FDA accelerated approval of KRESLADI, Rocket’s gene therapy for severe LAD-I.
Rocket states that monetizing the voucher provides meaningful non-dilutive capital and extends its cash runway into the second quarter of 2028. The company plans to use the proceeds to support its prioritized cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
Rocket Pharmaceuticals announced that the FDA has granted accelerated approval for KRESLADI, an autologous hematopoietic stem cell gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) who lack a matched sibling donor for transplant. The approval is based on increased neutrophil CD18 and CD11a surface expression, and continued approval may depend on confirming clinical benefit in ongoing studies and a post-marketing registry.
With KRESLADI’s approval, Rocket received a Rare Pediatric Disease Priority Review Voucher and plans to evaluate strategic options to monetize this voucher to enhance financial flexibility and shareholder value. The company highlighted that KRESLADI is the first FDA‑approved gene therapy for children with severe LAD-I, a life‑threatening ultra‑rare immunodeficiency characterized by recurrent serious infections and high early‑childhood mortality without treatment.
Rocket Pharmaceuticals entered into a new sales agreement with Cantor Fitzgerald & Co. to establish an at-the-market stock offering program. Under this arrangement, the company may, at its discretion, sell shares of its common stock with an aggregate offering price of up to $100,000,000 through Cantor as sales agent.
The shares will be issued under an existing shelf registration statement on Form S-3, supported by a prospectus supplement filed the same day. Cantor will sell the shares in transactions deemed at-the-market on Nasdaq, earning a cash commission of up to 3.0% of gross proceeds. Rocket can suspend or terminate sales at any time, and the program ends once all shares are sold or the agreement is otherwise terminated.
In connection with this new arrangement, Rocket terminated its prior at-the-market sales agreement with Cowen and Company, LLC. Legal opinions and the full sales agreement are filed as exhibits, providing the formal framework for potential future equity issuance.
Rocket Pharmaceuticals reported fourth-quarter 2025 net loss of $42,538, improving from $60,327 a year earlier. Full-year 2025 net loss was $223,123, compared with $258,746 in 2024, with net loss per share of $2.01 versus $2.73.
Total operating expenses for 2025 were $231,747, down from $273,205 in 2024, reflecting lower research and development and general and administrative spending and recorded restructuring charges of $3,231. Cash, cash equivalents and investments were $188,929 at December 31, 2025, versus $372,336 a year earlier, which the company says supports an operational runway into the second quarter of 2027.
Operationally, Rocket highlighted progress across its cardiovascular gene therapy programs. The pivotal Phase 2 trial of RP‑A501 for Danon disease is expected to resume in the first half of 2026, the KRESLADI™ BLA for severe LAD‑I has a March 28, 2026 PDUFA date, and first dosing in a Phase 1 study of RP‑A701 for BAG3‑related dilated cardiomyopathy is anticipated in mid‑2026.
Rocket Pharmaceuticals (RCKT) furnished a press release with certain financial information for the quarter ended September 30, 2025. The company submitted the release as Exhibit 99.1 under Item 2.02 of Form 8‑K.
The information is being furnished, not filed, meaning it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically referenced.
Rocket Pharmaceuticals (RCKT) announced FDA acceptance of its resubmitted BLA for KRESLADI (marne‑cel), an investigational lentiviral gene therapy for severe Leukocyte Adhesion Deficiency‑I (LAD‑I). The agency set a PDUFA date of March 28, 2026, establishing the formal timeline for a U.S. approval decision.
KRESLADI targets a rare, life‑threatening immune disorder that often proves fatal in childhood without allogeneic stem cell transplant. If approved, the company is eligible for a Rare Pediatric Disease Priority Review Voucher, which can carry strategic value for future regulatory filings. The company attached a press release (Exhibit 99.1) and cautioned that approval is not assured, consistent with forward‑looking statement disclosures.
Rocket Pharmaceuticals reported a board change. Director Pedro Granadillo resigned from the Board of Directors, effective September 30, 2025. The company stated that his decision did not involve any disagreement on matters related to operations, policies, or practices.
Rocket Pharmaceuticals, Inc. announced it voluntarily withdrew its U.S. Biologics License Application for mozafancogene autotemcel (RP-L102 / Fanskya) on October 3, 2025. The company stopped new internal investment in RP-L102 in July 2025 and also withdrew its MAA with the EMA in July 2025, citing a corporate prioritization to focus resources on programs with clearer regulatory and commercial paths. Rocket said the withdrawal reflects business and strategic considerations and does not reflect safety or efficacy concerns; it stated that data to date show RP-L102 has been generally well tolerated with no significant safety signals. The company will consider external partnerships and reserves the ability to re-engage regulators later if a sustainable pathway emerges.
Rocket Pharmaceuticals, Inc. (RCKT) disclosed the appointment of Dr. Fong to its board of directors in a current report. The filing states there are no arrangements or understandings between Dr. Fong and any other person regarding the appointment, no family relationships between Dr. Fong and company officers or directors, and no related person transactions as defined under Regulation S-K. The notice is brief and limited to governance disclosures; it confirms the director addition and the absence of conflicts or reportable transactions, giving investors a clear, administrative update on the board composition and compliance with related‑party disclosure rules.
Rocket Pharmaceuticals announced the separation of Dr. Kinnari Patel and related consulting arrangements. Under a Separation and Release Agreement dated September 11, 2025, Dr. Patel will receive her salary and benefits through December 31, 2025, payment for accrued unused paid time off, a lump sum severance payment of $482,040 conditioned on signing a release within seven days, and a lump sum healthcare allowance of $30,045 to cover approximately ten months of COBRA premiums. Concurrently, the company entered a Consulting Agreement effective after the release revocation period and continuing through December 31, 2026, under which Dr. Patel will provide general consulting services for an aggregate retainer of $582,156. The Consulting Agreement preserves her restricted stock units and options during the consulting period. The Separation and Consulting Agreements are filed as Exhibits 10.1 and 10.2 and are incorporated by reference.
Rocket Pharmaceuticals reported a leadership change in its finance organization. Chief Financial Officer Aaron Ondrey resigned on August 20, 2025, with his departure effective September 5, 2025, as he leaves to pursue other opportunities.
On August 25, 2025, the company appointed Martin Wilson, its General Counsel, Chief Corporate Officer and Corporate Secretary, as interim Principal Financial Officer, effective September 8, 2025. Wilson joined Rocket in November 2021 and became Chief Corporate Officer in March 2024, bringing nearly 20 years of legal, compliance and executive experience in the life sciences industry, including senior roles at Ichnos Sciences and Teligent. The company states there are no family relationships or related-party transactions with Wilson beyond his existing compensation.
Rocket Pharmaceuticals filed a current report stating that the U.S. Food and Drug Administration has lifted the clinical hold on its pivotal Phase 2 trial of RP‑A501, a gene therapy candidate for the treatment of Danon disease. This means the planned pivotal study can now proceed under FDA oversight. The company also issued a press release about this development, which is attached as an exhibit to the report.
Item 2.02: On August 7, 2025 Rocket Pharmaceuticals, Inc. announced preliminary financial information for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1. The filing states the exhibit is furnished, not filed under Item 2.02 and therefore not subject to Section 18 liability.
Item 5.02: Effective December 31, 2025, Dr. Kinnari Patel will leave the Company to join RTW Investments LP as a venture partner. As of August 8, 2025 she no longer serves as President, Head of Research and Development and will assist in transitioning her duties to other executives. Exhibits include the press release (99.1) and Inline XBRL cover page (104). The report is signed by Martin Wilson on August 7, 2025.
Rocket Pharmaceuticals, Inc. (RCKT) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting.
- Quorum: 91,366,461 shares represented, or approximately 85.56% of outstanding common stock.
- Director elections: All ten nominees were elected. “For” votes ranged from 55.35 M to 78.60 M, with David P. Southwell receiving the highest opposition (23.79 M withheld).
- Auditor ratification: EisnerAmper LLP approved with 90.70 M For, 0.14 M Against, 0.53 M Abstain.
- Say-on-Pay: Executive compensation passed on an advisory basis (77.19 M For, 1.44 M Against, 0.52 M Abstain).
The vote results indicate broad shareholder support for the board, management and governance practices; no other material events were disclosed.